Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) - Net Assets

Latest as of March 2026: CN¥2.35 Billion CNY ≈ $343.22 Million USD

Based on the latest financial reports, Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) has net assets worth CN¥2.35 Billion CNY (≈ $343.22 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.01 Billion ≈ $439.90 Million USD) and total liabilities (CN¥660.73 Million ≈ $96.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥2.35 Billion
% of Total Assets	78.02%
Annual Growth Rate	12.74%
5-Year Change	5.96%
10-Year Change	29.33%
Growth Volatility	71.15

Jilin Jian Yisheng Pharmaceutical Co Ltd - Net Assets Trend (2006–2025)

This chart illustrates how Jilin Jian Yisheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Jilin Jian Yisheng Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual net assets of Jilin Jian Yisheng Pharmaceutical Co Ltd from 2006 to 2025. For live valuation and market cap data, see 002566 market cap overview.

Year	Net Assets	Change
2025-12-31	CN¥2.33 Billion ≈ $340.85 Million	-0.18%
2024-12-31	CN¥2.33 Billion ≈ $341.45 Million	+0.04%
2023-12-31	CN¥2.33 Billion ≈ $341.31 Million	+3.69%
2022-12-31	CN¥2.25 Billion ≈ $329.16 Million	+2.33%
2021-12-31	CN¥2.20 Billion ≈ $321.68 Million	+3.10%
2020-12-31	CN¥2.13 Billion ≈ $312.01 Million	+3.61%
2019-12-31	CN¥2.06 Billion ≈ $301.13 Million	+4.69%
2018-12-31	CN¥1.97 Billion ≈ $287.63 Million	+3.61%
2017-12-31	CN¥1.90 Billion ≈ $277.60 Million	+5.33%
2016-12-31	CN¥1.80 Billion ≈ $263.55 Million	+3.21%
2015-12-31	CN¥1.75 Billion ≈ $255.36 Million	-0.34%
2014-12-31	CN¥1.75 Billion ≈ $256.24 Million	+4.43%
2013-12-31	CN¥1.68 Billion ≈ $245.38 Million	+5.51%
2012-12-31	CN¥1.59 Billion ≈ $232.57 Million	+4.97%
2011-12-31	CN¥1.51 Billion ≈ $221.56 Million	+321.29%
2010-12-31	CN¥359.40 Million ≈ $52.59 Million	+27.90%
2009-12-31	CN¥280.99 Million ≈ $41.12 Million	+27.79%
2008-12-31	CN¥219.89 Million ≈ $32.18 Million	+6.96%
2007-12-31	CN¥205.59 Million ≈ $30.08 Million	-13.87%
2006-12-31	CN¥238.69 Million ≈ $34.93 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jilin Jian Yisheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 632.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥918.25 Million	41.15%
Other Components	CN¥1.31 Billion	58.85%
Total Equity	CN¥2.23 Billion	100.00%

Jilin Jian Yisheng Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jilin Jian Yisheng Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Nanjing Chixia Development Co Ltd SHG:600533	$311.91 Million
Fennec Pharmaceuticals Inc NASDAQ:FENC	$311.94 Million
Idun Industrier AB Series B ST:IDUN-B	$311.95 Million
Harbin VITI Electronics Corp SHG:603023	$311.98 Million
Deva Holding AS IS:DEVA	$311.80 Million
Worldex Industry & Trading Co. Ltd KQ:101160	$311.62 Million
Dividend Growth Split Corp TO:DGS	$311.50 Million
Handsome KO:020000	$311.47 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jilin Jian Yisheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,235,606,654 to 2,231,510,781, a change of -4,095,873 (-0.2%).
Net income of 28,999,287 contributed positively to equity growth.
Dividend payments of 45,607,753 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥29.00 Million	+1.3%
Dividends Paid	CN¥45.61 Million	-2.04%
Other Changes	CN¥12.51 Million	+0.56%
Total Change	CN¥-	-0.18%

Book Value vs Market Value Analysis

This analysis compares Jilin Jian Yisheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.96x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 6.70x to 0.96x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.96	CN¥6.44	x
2007-12-31	CN¥0.83	CN¥6.44	x
2008-12-31	CN¥0.88	CN¥6.44	x
2009-12-31	CN¥1.13	CN¥6.44	x
2010-12-31	CN¥1.45	CN¥6.44	x
2011-12-31	CN¥4.85	CN¥6.44	x
2012-12-31	CN¥4.74	CN¥6.44	x
2013-12-31	CN¥4.93	CN¥6.44	x
2014-12-31	CN¥5.21	CN¥6.44	x
2015-12-31	CN¥5.22	CN¥6.44	x
2016-12-31	CN¥5.26	CN¥6.44	x
2017-12-31	CN¥5.45	CN¥6.44	x
2018-12-31	CN¥5.61	CN¥6.44	x
2019-12-31	CN¥5.84	CN¥6.44	x
2020-12-31	CN¥6.03	CN¥6.44	x
2021-12-31	CN¥6.29	CN¥6.44	x
2022-12-31	CN¥6.51	CN¥6.44	x
2023-12-31	CN¥6.75	CN¥6.44	x
2024-12-31	CN¥6.76	CN¥6.44	x
2025-12-31	CN¥6.74	CN¥6.44	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jilin Jian Yisheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.30%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 4.53%
• Asset Turnover: 0.22x
• Equity Multiplier: 1.33x
Recent ROE (1.30%) is below the historical average (7.44%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	9.83%	10.37%	0.67x	1.42x	CN¥-397.47K
2007	17.63%	13.48%	0.78x	1.67x	CN¥15.63 Million
2008	18.88%	13.27%	0.90x	1.58x	CN¥19.45 Million
2009	21.81%	14.73%	0.97x	1.53x	CN¥33.10 Million
2010	24.43%	16.98%	1.00x	1.44x	CN¥51.77 Million
2011	6.46%	18.24%	0.34x	1.06x	CN¥-52.94 Million
2012	6.16%	16.09%	0.36x	1.06x	CN¥-60.26 Million
2013	5.27%	13.56%	0.34x	1.14x	CN¥-78.30 Million
2014	5.57%	12.24%	0.32x	1.44x	CN¥-76.64 Million
2015	0.63%	1.33%	0.31x	1.53x	CN¥-161.56 Million
2016	0.76%	1.41%	0.35x	1.53x	CN¥-160.89 Million
2017	3.33%	5.81%	0.39x	1.47x	CN¥-120.22 Million
2018	3.72%	7.08%	0.38x	1.38x	CN¥-116.48 Million
2019	3.96%	7.56%	0.41x	1.29x	CN¥-116.62 Million
2020	4.01%	9.50%	0.30x	1.40x	CN¥-119.51 Million
2021	4.61%	10.94%	0.31x	1.38x	CN¥-112.16 Million
2022	3.86%	10.01%	0.28x	1.38x	CN¥-132.40 Million
2023	4.24%	11.10%	0.28x	1.36x	CN¥-128.58 Million
2024	2.33%	7.79%	0.23x	1.33x	CN¥-171.47 Million
2025	1.30%	4.53%	0.22x	1.33x	CN¥-194.15 Million

Industry Comparison

This section compares Jilin Jian Yisheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $5,212,589,599
Average return on equity (ROE) among peers: 2.06%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jilin Jian Yisheng Pharmaceutical Co Ltd (002566)	CN¥2.35 Billion	9.83%	0.28x	$311.88 Million
Shenzhen CAU Technology Co Ltd (000004)	$1.40 Billion	-0.26%	0.06x	$53.47 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403)	$966.91 Million	19.23%	0.71x	$1.50 Billion
Nanhua Bio Medicine Co Ltd (000504)	$128.43 Million	-28.90%	2.15x	$378.62 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518)	$512.78 Million	-14.68%	0.29x	$470.05 Million
Chengzhi Shareholding Co Ltd (000990)	$1.69 Billion	3.06%	0.97x	$1.54 Billion
Hualan Biological EngineeringInc (002007)	$13.85 Billion	7.86%	0.18x	$3.43 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030)	$428.60 Million	11.05%	0.37x	$1.14 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252)	$29.65 Billion	6.00%	0.08x	$4.52 Billion
Baolingbao Biology Co Ltd (002286)	$1.45 Billion	1.65%	0.22x	$496.75 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287)	$2.05 Billion	15.59%	0.13x	$1.64 Billion

About Jilin Jian Yisheng Pharmaceutical Co Ltd

SHE:002566 China Biotechnology

Market Cap

$311.88 Million

CN¥2.13 Billion CNY

Market Cap Rank

#14723 Global

#4394 in China

Share Price

CN¥6.44

Change (1 day)

-0.92%

52-Week Range

CN¥6.44 - CN¥9.05

All Time High

CN¥19.38